Nordic Life Science 1
TOP STORIES BUSINESS the company will test whethe
r one of its drug candidates, which blocks a protein that is very active in acute respiratory distress syndrome (ARDS) and other types of lung infections, is an effective treatment. “The treatment can be beneficial for COVID-19 patients, as well as for those who suffer from seasonal flu, because it works in the same way. It might also provide relief for those suffering from chronic obstructive pulmonary disease (COPD),” says Stefan K Nilsson, CEO, Lipigon. Nilsson hopes that the The planned changes and renewal will affect the entire R&D organization and may result in personnel reductions. implement the planned changes and refocusing of Orion’s R&D, and the organizational changes that support these, Orion will launch co-operation negotiations concerning its R&D function (over 500 employees) in Finland – in Espoo, Turku and Kuopio. The negotiations will concern all members of staff in all personnel groups in R&D in Finland. The negotiations may result in personnel reductions of a maximum of 25 persons. The plan is to implement some of the possible personnel reductions through retirement, part-time work and training opportunities. THE COMPANY MAY also transfer persons affected by the negotiations to other roles in the group. Should redundancies occur, they would take place during 2020. Stefan K Nilsson, CEO, Lipigon 10 NORDICLIFESCIENCE.ORG research will allow Lipigon to start human trials of its drug candidate sooner. PHOTO TOMI PARKKONEN PHOTO PATRICK TRÄGÅRDH